Third Rock Ventures
Third Rock Ventures is an investor and company builder focused on creating and advancing biotechnology companies that translate scientific innovation into medicines. The firm emphasizes company formation, scientific and operational support across discovery and development, and partnerships to accelerate therapies for patients across immunology, genetic medicine, oncology, rare diseases and other therapeutic areas.
Industries
Nr. of Employees
small (1-50)
Portfolio
Announced combination of vopimetostat and daraxonrasib with reported 92% objective response rate in pancreatic cancer (press release linked).
#Oncology / Therapeutics
Acquisition announced by UCB to expand its immunology pipeline (press release linked).
#Immunology / T-cell engagers
Otarmeni (lunsotogene parvec-cwha), an original asset from Decibel Therapeutics (acquired by Regeneron in 2023), received FDA approval as the first gene therapy for genetic hearing loss.
#Genetic medicine / Gene therapy
Novartis to acquire Synnovation’s pan-mutant selective PI3Kα inhibitor program (press release linked).
#Oncology / Targeted therapies
AQVESME (mitapivat) approved by FDA for anemia in alpha- and beta-thalassemia; mitapivat previously approved and marketed as PYRUKYND for PK deficiency indication.
#Hematology / Rare disease
Announced combination of vopimetostat and daraxonrasib with reported 92% objective response rate in pancreatic cancer (press release linked).
#Oncology / Therapeutics
Acquisition announced by UCB to expand its immunology pipeline (press release linked).
#Immunology / T-cell engagers
Otarmeni (lunsotogene parvec-cwha), an original asset from Decibel Therapeutics (acquired by Regeneron in 2023), received FDA approval as the first gene therapy for genetic hearing loss.
#Genetic medicine / Gene therapy
Novartis to acquire Synnovation’s pan-mutant selective PI3Kα inhibitor program (press release linked).
#Oncology / Targeted therapies
AQVESME (mitapivat) approved by FDA for anemia in alpha- and beta-thalassemia; mitapivat previously approved and marketed as PYRUKYND for PK deficiency indication.
#Hematology / Rare disease